The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer
Molly Li, MMBS, Queen Elizabeth Hospital, Hong Kong, walks through how continued osimertinib administration alongside chemotherapy reduces progression in patients with EGFR-mutant non-small cell lung cancer (NSCLC). Central nervous system (CNS) progression is common in patients with epidermal growth factor receptor (EGFR) mutations, which are prevalent in Asia. Standard treatment for these patients who fail to respond to osimertinib is chemotherapy, although this has limited activity in the CNS. A retrospective analysis of 180 patients that suggests continuing osimertinib use alongside chemotherapy may reduce CNS progression. Results showed that CNS progression and salvage whole brain radiation rate was reduced in the chemotherapy and osimertinib cohort, despite progression-free survival being statistically insignificant. Dr Li states that these results support the conclusions drawn from the FLAURA2 trial (NCT04035486). This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
